Dose-dependent effects of eltrombopag iron chelation on platelet formation
Abstract: Iron deficiency is associated with thrombocytosis in patients, although thrombocytopenia can occur in cases of severe iron deficiency anemia. Eltrombopag (EP), a thrombopoietic agent approved for immune thrombocytopenia, also acts as an iron chelator. Our study demonstrates that megakaryoc...
Saved in:
| Main Authors: | Elisabetta Bassi, Vittorio Abbonante, Alicia Aguilar, Hana Raslova, James B. Bussel, Christian Andrea Di Buduo, Alessandro Malara, Alessandra Balduini |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Blood Vessels, Thrombosis & Hemostasis |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950327225000178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Megakaryocyte contribution to bone marrow fibrosis: many arrows in the quiver
by: Alessandro Malara, et al.
Published: (2018-11-01) -
Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag
by: Faiz Anwer, et al.
Published: (2015-01-01) -
An Uncommon Association: Eltrombopag and Autoimmune Hepatitis
by: Fady Salama, et al.
Published: (2025-01-01) -
Outside-in signalling generated by a constitutively activated integrin αIIbβ3 impairs proplatelet formation in human megakaryocytes.
by: Loredana Bury, et al.
Published: (2012-01-01) -
Sex and Gender Differences in Iron Chelation
by: Sarah Allegra, et al.
Published: (2024-12-01)